Fig. 2.

High IL-6 levels are associated with reduced clinical outcomes following treatment with Ate/Bev in HCC. Treatment outcomes of the (A–C) discovery cohort (n = 84) and (D–F) validation cohort (n = 81). (A and D) Bar charts showing the best response to Ate/Bev as determined by IL-6 levels. (B, C, E, and F) Kaplan–Meier curves showing PFS and OS according to IL-6 levels. Values of p were calculated using the log-rank test. HRs and 95% CIs are shown in the survival curves. Ate/Bev, atezolizumab and bevacizumab; HCC, hepatocellular carcinoma; HR, hazard ratio; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.